BioVie Inc.

BioVie volume spikes that signals EMA10 possibility.

238
The company announced the completion of its direct offering, raising $6.66 million through the sale of 4.4 million shares at $1.50 per share. Also they issued unregistered warrants for an additional 4.4 million shares, exercisable in 6 months at $1.37 per share, with proceeds primarily supporting working capital.
There is remarkable volume increase as a result. Historically, each spike in volume has encountered resistance at EMA10 weekly. While the stock remains ultra-highly volatile, a price above $9 does not seem impossible at this stage.
Nota
Earlier, I mistakenly referred to the weekly EMA50 instead of EMA10. Correcting this, the potential target is now the weekly EMA40, currently around $8.77.

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.